$3,550,000 of AMGEN INC lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to drug pricing Issues related to Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.3345, PBM Price Transparency and Accountability Act H.R. 6166, Lowering Drug Costs for American Families Act S.3019 - No Big Blockbuster Bailouts Act H.Res. 928 - Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act HR 5526 Biosimilar Red Tape Elimination Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 5509 Safe Step act HR 5256 340B Access Act HR 4581 340B Patients Act S2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act H.R. 6703 Lower Health Care Premiums for All Americans Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act H.Res. 928 Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to patents and taxes Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling Issues related to patents and taxes S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S.2296-- NDAA (FY 2026 National Defense Authorization Act-- BIOSECURE language) S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) HR 6485 Skinny Labels Big Saving Act Issues related to tariffs."
You can find more data on corporate lobbying on Quiver Quantitative.
AMGN Congressional Stock Trading
Members of Congress have traded $AMGN stock 6 times in the past 6 months. Of those trades, 2 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/03.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 2 times. They made 2 purchases worth up to $30,000 on 10/24, 09/11 and 0 sales.
- REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 09/25.
- SENATOR SHELDON WHITEHOUSE sold up to $15,000 on 09/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AMGN Insider Trading Activity
AMGN insiders have traded $AMGN stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by insiders over the last 6 months:
- MURDO GORDON (EVP, Global Commercial Ops) sold 6,879 shares for an estimated $2,317,071
- NANCY A. GRYGIEL (SVP & CCO) has made 0 purchases and 3 sales selling 4,406 shares for an estimated $1,434,946.
- RACHNA KHOSLA (SVP, Business Development) sold 890 shares for an estimated $299,255
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AMGN Hedge Fund Activity
We have seen 1,250 institutional investors add shares of AMGN stock to their portfolio, and 1,279 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 3,816,157 shares (+72.2%) to their portfolio in Q3 2025, for an estimated $1,076,919,505
- CAPITAL WORLD INVESTORS added 1,935,876 shares (+11.5%) to their portfolio in Q3 2025, for an estimated $546,304,207
- PRIMECAP MANAGEMENT CO/CA/ removed 924,100 shares (-8.7%) from their portfolio in Q3 2025, for an estimated $260,781,020
- NATIONAL BANK OF CANADA /FI/ added 866,166 shares (+240.5%) to their portfolio in Q3 2025, for an estimated $244,432,045
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 656,935 shares (+5.1%) to their portfolio in Q3 2025, for an estimated $185,387,057
- PERRITT CAPITAL MANAGEMENT INC removed 599,055 shares (-99.6%) from their portfolio in Q3 2025, for an estimated $169,053,321
- WOODTRUST FINANCIAL CORP removed 588,232 shares (-98.8%) from their portfolio in Q3 2025, for an estimated $165,999,070
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AMGN Analyst Ratings
Wall Street analysts have issued reports on $AMGN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 12/03/2025
- Piper Sandler issued a "Overweight" rating on 11/14/2025
- B of A Securities issued a "Underperform" rating on 09/26/2025
To track analyst ratings and price targets for AMGN, check out Quiver Quantitative's $AMGN forecast page.
AMGN Price Targets
Multiple analysts have issued price targets for $AMGN recently. We have seen 11 analysts offer price targets for $AMGN in the last 6 months, with a median target of $319.0.
Here are some recent targets:
- Courtney Breen from Bernstein set a target price of $335.0 on 01/20/2026
- Gregory Renza from Truist Securities set a target price of $319.0 on 01/08/2026
- Michael Yee from UBS set a target price of $380.0 on 01/07/2026
- Terence Flynn from Morgan Stanley set a target price of $304.0 on 12/12/2025
- Mohit Bansal from Wells Fargo set a target price of $325.0 on 12/10/2025
- Evan David Seigerman from BMO Capital set a target price of $372.0 on 12/03/2025
- David Amsellem from Piper Sandler set a target price of $381.0 on 11/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
